Navigation Links
SAFC Adopts Targeted Approach to Reach Pre-Registration
Date:1/27/2009

combined with expertise in analytical testing, manufacturing, packaging, quality control, and compliance services can speed the development process and lower costs for customers, enabling faster time to market. For more information visit www.safcsupplysolutions.com.

About Sigma-Aldrich: Sigma-Aldrich(R) is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 37 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

SAFC(R), SAFC Supply Solutions(R) and Sigma-Aldrich(R) are registered tradema
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Coley Pharmaceutical Group Adopts Shareholder Rights Plan
2. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
3. Atom Medical Adopts Masimo Rainbow SET Technology
4. Informed Medical Communications Adopts Newly Enhanced Compliance Policy
5. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
6. European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
7. Gowlings Adopts RFID and Unifies Practice Management
8. BMP Sunstone Adopts Voluntary Executive Compensation Restrictions in 2008 and 2009
9. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ABY,BC,Nov.23/PRNewswire/-InimexPharmaceuticals,In...Ph.DasitsPresidentandCEO. ,, Abramsbringsmoreth...Inimex.Heisaco-inventorofthenuclearmedicineimaging...atthey,plcwherehewasManager,BiomedicalResearchWorl...angley,BCandwasPresidentandCEOfrom1996to2006.AnorM...
(Date:11/20/2009)...Latin American countries have an opportunity to ta...searchers from the University of Valencia (UV), wo...tudied the productive fabric of the Spanish biotec... food and plant sectors have more clout than those...as applied to food and plants has been overlooked ...
(Date:11/20/2009)..., SEATTLE, Nov. 20 Cell...nnounced today that the Ninth Circuit Court of App...d that CTI should be allowed to pursue all of its ...ck to the District Court for trial. CTI filed a c...d-party reimbursement consultant for CTI,s product...
(Date:11/19/2009)...EATTLE, Nov. 19 Omeros C...ted financial results for the third quarter ended ...tember 30, 2009, Omeros reported a net loss of $3....t loss of $7.4 million, or $2.54 per share, for th...eptember 30, 2009, the Company reported a net loss...
Breaking Biology Technology:Inimex Announces Appointment of New CEO 2Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8
...ug Royalty LP 2 (DRC) announced,today the purchase...rldwide,royalty interest in PEG-INTRON for $92.5M.... 2012 should certain royalty recognition levels be...oved for the treatment of,Hepatitis C and is marke.... Speaking on behalf of DRC, Paul Kirkconnell, Ma...
...Aug. 27 NeurogesX, Inc.,(Nasdaq: NGSX ), a bioph...ain management therapies, announced today that it ...the Biotech Industry Conference on Thursday,Septem...Executive Officer,and Stephen Ghiglieri, Chief Fin...hursday, September 6, 2007 Time: 2:00 p.m. ...
...DA and Committed to Addressing Unmet Needs of ... - - Conference Call Scheduled for 4:3... Inc.,(Nasdaq: IDMI ) announced today that it rec...nd Drug Administration (FDA) after completing the,...nvestigational drug,mifamurtide (L-MTP-PE), former...
Other Biology Technology:Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2NeurogesX to Present at BioCentury's NewsMakers in the Biotech Industry Conference 2NeurogesX to Present at BioCentury's NewsMakers in the Biotech Industry Conference 3IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma 2IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma 3IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma 4IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma 5IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma 6IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma 7
(Date:11/22/2009)... WASHINGTON, D.C. November 18, 2009 -- A butterfly...and used for sipping -- but it works more like a p...son University. He hopes to borrow the tricks of t...hat can sample the fluid inside of cells. , Korn...ual Meeting of the American Physical Society,s (AP...
(Date:11/22/2009)...cientists at the Brain Research Centre, a partners...of Medicine and Vancouver Coastal Health Research ...e mechanism by which brain cells die following a s...damage. The results of the study were recently pub...a stroke, many brain cells continue to die even af...
(Date:11/20/2009)... NJIT researchers are at work on many scientific a...oundation has recently provided support that total...he following investigators under the American Reco...archers have been awarded grants for investigation...d professor of physics, will enhance the capabilit...
Breaking Biology News(10 mins):New understanding about mechanism for cell death after stroke leads to possible therapy 2NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Southern California Surgical Center 28heart411 com 29 Specializes in Mitral Valve Replacement 52836 1Southern California Surgical Center 28heart411 com 29 Specializes in Mitral Valve Replacement 52836 2Human Genome Sciences Announces Proposed Public Offering of Common Stock 13215 1Human Genome Sciences Announces Proposed Public Offering of Common Stock 13215 2Human Genome Sciences Announces Proposed Public Offering of Common Stock 13215 3Anthem Blue Cross and Blue Shield Introduces a Health Insurance Solution With a Special Boulder Flair to Chamber Members 52834 1Anthem Blue Cross and Blue Shield Introduces a Health Insurance Solution With a Special Boulder Flair to Chamber Members 52834 2
... The earliest humans almost certainly walked uprig...en half the speed of modern man, new research sugg...nted to the BA (British Association for the Advanc...uesday proposes that if early humans lacked an Ac...hen their ability to run would have been severely ...
...COKEEK, Md., Sept. 10 Beretta U.S.A. Corp. announ...U.S. Army and U.S. Navy for a,total of 10,576 M9 p...he,purchase orders were issued against a multi-yea...y, which serves as executive purchasing agent of t...rces. "We are always honored to be given the oppo...
...nference Embarks on New Strategic Direction in 21s... and HDD Suppliers Under One Roof, SUNNYVALE, Cal...nd its robust dynamic supply chain, IDEMA today an...he premier storage industry event, to be,held on S...a Clara,Convention Center in Santa Clara, Californ...
Other Biology News:Was ability to run early man's Achilles heel? 2Was ability to run early man's Achilles heel? 3U.S. Army and Navy Purchase Over 10,000 New Beretta M9 Pistols 2IDEMA Reveals Program Highlights for DISKCON USA 2007 2IDEMA Reveals Program Highlights for DISKCON USA 2007 3IDEMA Reveals Program Highlights for DISKCON USA 2007 4
Mouse Anti-beta-lactoglobulin Monoclonal Antibody, Unconjugated, Clone CD-2 from Cosmo Bio Co., Ltd.
...ti-AP-2 α, clone 8G8/5 GenBank Accession Nu...an AP-2alpha/gamma fusion protein corresponding to...s 278-450 of human AP-2γ Formulation: 0.1M T...e before the addition of glycerol to 30% Quality A...
MMP-2/MMP-9 Inhibitor IV [SB-3CT] from CHEMICON
Costar 6 Well Cell Culture Plate, 9.5 cm2, 34.8 mm Diam. Well, Sterile from Sigma-Aldrich
Biology Products: